CarboHyde Solutions’ Post

🧬 Faced with the challenge to reliably synthesize and produce complex plasmid DNAs used in the production of viral vectors for gene therapy, Novel Biotechnology submitted 51 UTR sequences for complexity screening to three commonly used DNA synthesis vendors, as well as to Ansa. As they reported in this poster, the majority of the sequences were rejected outright by most vendors, but 100% were accepted for synthesis by Ansa. "Here we have shown how innovations in DNA synthesis and assembly enable the routine production of plasmid designs that would have been difficult, if not impossible, to generate using conventional techniques. These innovations include the use of Ansa’s enzymatic DNA synthesis platform in conjunction with Novel Bio’s in-house workflows for plasmid DNA production. The use of these technologies enabled us to seamlessly deliver on a complicated gene therapy project. Without this capability, this project would have become considerably more complex and costly." Thanks for sharing this success story, Novel Biotechnology Inc.! Interested in putting our #complexDNA synthesis services to the test on your project? Learn how to join our Early Access Program: https://lnkd.in/grMhxgfN #DNAsynthesis #longDNA #Ansamers #biotech #synbio #SyntheticDNA #DNAInnovation #complexDNA #customDNA #AnsamerAnswers

Don't forget to join us today at 3pm GMT / 4pm CET /10am EST for the first webinar in our 3 part series on CRISPR and Gene Editing ONLINE. If you can't make it you can still register to catch up on-demand: https://lnkd.in/dA9KycdX   Today, we'll be discussing advances in gene editing systems. We'll be highlighting their applications and benefits and discussing the future of gene editing technologies, both from a technological standpoint and in relation to future therapeutics. Talk 1: Precise Transcript Targeting by CRISPR-Csm Complexes David Colognori, Post-Doctoral Associate, Doudna Lab, UC Berkeley    Talk 2: PRCISR CRISPR: Vivlion’s CRISPR-enabled PCR-free discovery platform   Martin Wegner, Head of R&D, Vivlion GmbH    Talk 3: Precise and Versatile Genome Engineering with Prime Editing  Andrew Anzalone, Head of the Prime Editing Platform and Scientific Co-Founder, Prime Medicine, Inc. #CRISPR #geneediting

🔬 Are you Struggling to achieve desired results in Cell and Gene Therapy, Viral Vector, and vaccine manufacturing using adherent or suspension cell culture bioprocessing platforms? Is troubleshooting issues and maintaining consistent product quality becoming a challenge? OmniBRx has the solution for you! Join Anandprakash Joshi at VIROCON 2023, organized by ICAR- National Research Centre for Banana - India and the Indian Virological Society, to explore our innovative platform. With OmniBRx, you can overcome troubleshooting issues and ensure consistent product quality. Our Adherent solutions (CellBRx and SeedBRx-IST) and Suspension solutions (MiniBRx and PerfBRx) are complemented by groundbreaking automation options. Imagine achieving efficient, scalable, and affordable bioprocessing without breaking the bank. OmniBRx makes this a reality. Let's collaborate and innovate together to overcome your bioprocessing challenges! See you at the conference! 📅🤝 #Biotechexpo #biotechnology #virology #vaccinedevelopment #bioprocessing

#LipidNanoparticles #GeneTherapy #NucleicAcidDelivery | 𝗖𝗮𝗻 𝗹𝗶𝗽𝗶𝗱 𝗻𝗮𝗻𝗼𝗽𝗮𝗿𝘁𝗶𝗰𝗹𝗲𝘀 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀? 🟣 𝗔𝗶𝗺: Explore the 60-year evolution of lipid nanoparticles (LNPs) in delivering genetic information to target cells. 🟣 𝗞𝗲𝘆 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀: Advances in lipid-based systems have enabled the development of LNPs for nucleic acid delivery. Clinically approved examples include COVID-19 LNP mRNA vaccines and Onpattro (patisiran) for treating hATTR. Research highlights the role of positively charged cationic lipids and ionizable cationic lipids in developing effective LNPs. 🟣 𝗧𝗮𝗸𝗲 𝗛𝗼𝗺𝗲 𝗠𝗲𝘀𝘀𝗮𝗴𝗲: LNPs represent a significant breakthrough in gene therapy, offering potential delivery solutions for various genetic treatments. Check here for more https://lnkd.in/gNXuWQ6h and a big thank you to Pieter Cullis & Phil Felgner for their valuable research in Nature Reviews Drug Discovery. 𝗪𝗲𝗹𝗰𝗼𝗺𝗲 𝘁𝗼 NanoSphere – 𝘆𝗼𝘂𝗿 𝗽𝗿𝗲𝗺𝗶𝗲𝗿 𝗱𝗲𝘀𝘁𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗳𝗼𝗿 𝗻𝗮𝗻𝗼𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲, 𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘇𝗶𝗻𝗴 𝗶𝗻 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 𝗶𝗻 𝗻𝗮𝗻𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗮𝗻𝗱 𝗻𝗼𝗻-𝘃𝗶𝗿𝗮𝗹 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺𝘀 (𝗟𝗡𝗣𝘀) 𝗳𝗼𝗿 𝗻𝘂𝗰𝗹𝗲𝗶𝗰 𝗮𝗰𝗶𝗱𝘀.  Follow us for more: https://lnkd.in/ecNd8VDP

#geneediting Exciting News for the Biotech Community! 🧬 Cyagen Offers Cutting-Edge Custom Gene Editing Services! Are you in need of precise and reliable gene editing services for your research or biotech development? Look no further! Cyagen provides a comprehensive range of custom gene editing services, including gene knockouts, knock-ins, point mutations, overexpression, and shRNA interference. Whether for basic gene function studies, drug screening, or gene therapy, Cyagen has got you covered. ✨ What's more, for a limited time, Cyagen is offering a special discount on its gene editing services if you order by December 31st, 2024. ⏰ Take advantage of this promotion to advance your research and development projects! Key Features: ✅ Flexible project types and deliverables tailored to your specific needs ✅ Fast turnaround times, with some services available in as little as 6 weeks ✅ Professional project management and Ph.D.-provided technical support available 24/7 ✅ Strict quality control to ensure the highest standards in deliverables Explore the full range of services and popular cell lines available for gene editing: https://lnkd.in/g_KPEmi5 Don't miss out on this exceptional opportunity to elevate your research and development endeavors. Contact us today and unlock the potential of custom gene editing in advancing your scientific pursuits! #genetherapy #Biotech #ResearchAndDevelopment #Cyagen #CustomGeneEditingServices #ScienceAndInnovation #biosciences #biotechnology #biology #scienceandtechnology

14 approved gene therapies, But at what stages of development? Here's the gene therapy landscape 👇 Over 1300 IND applications have been submitted for gene therapies to date. The recent 2023 approvals for 𝘝𝘺𝘫𝘶𝘷𝘦𝘬, 𝘌𝘭𝘦𝘷𝘪𝘋𝘺𝘦𝘴, 𝘢𝘯𝘥 𝘙𝘰𝘤𝘵𝘢𝘷𝘪𝘢𝘯 have ignited a surge of activity in this space as well as 𝐄𝐱𝐚-𝐜𝐞𝐥 𝐛𝐞𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐂𝐑𝐈𝐒𝐏𝐑-𝐛𝐚𝐬𝐞𝐝 𝐠𝐞𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 to receive regulatory approval too. The PDF below outlines the private vs public company landscape. ➡️ Notably, the limited presence of companies in the pre-clinical stage for ex vivo gene therapy can be attributed to challenges in precision genetic modifications, safety concerns, stringent regulations, expensive + resource-intensive development, and strategic decision-making. (𝘈𝘭𝘭 𝘤𝘳𝘦𝘥𝘪𝘵 𝘵𝘰 𝘛𝘋, 𝘤𝘰𝘸𝘦𝘯 𝘢𝘯𝘥 𝘤𝘰, 𝘱𝘭𝘶𝘴 𝘩𝘪𝘨𝘩𝘭𝘪𝘨𝘩𝘵𝘦𝘥 𝘤𝘰𝘮𝘱𝘢𝘯𝘺 𝘳𝘦𝘱𝘰𝘳𝘵𝘴). P.S. - Want to stay ahead of the biotech revolution? Sign up for FREE to my 𝐂𝐆𝐓𝐰𝐞𝐞𝐤𝐥𝐲 newsletter and discover the newest companies, clinical updates and breakthroughs this week, here: https://lnkd.in/etZK5kzZ 𝐇𝐚𝐯𝐞 𝐚𝐧𝐲 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐛𝐞𝐞𝐧 𝐦𝐢𝐬𝐬𝐞𝐝? #genetherapy #biotech #CGTweekly #regenerativemedicine

#AAVdownstream challenges: expert insights #AAVvectors are a primary delivery mechanism for #genetherapies due to low immunogenicity, long lasting gene expression, and the ability to target specific tissues. The field of #AAV manufacturing is rapidly expanding, but there are challenges in the downstream processing of these #viralvectors. Next month, an expert panel including Nathalie Clément (VP, Vector Development for Translational Gene Therapies, Siren Biotechnology), Matt Roach (Director of AAV Production, BridgeBio), Nicolas Laroudie (Senior Field Application Scientist, Thermo Fisher Scientific), and William Kish (Principal Scientist - Downstream Process Sciences Engineering, Taysha Gene Therapies) will provide an opportunity to learn more about the latest trends and issues in #AAVmanufacturing, and specifically, how to address the most common downstream processing challenges Register for this #webinar below:

Potential for driving down vector costs and creating a more robust supply chain? In the world of gene therapy, a recent breakthrough promises to revolutionize manufacturing processes, especially in Adeno-Associated Virus (AAV) production. The discovery of Membrane-Associated Accessory Protein (MAAP) and its role in AAV biology has sparked a focused exploration into optimizing manufacturing processes. A recent study by Schieferecke et al. outlines a directed evolution strategy to engineer MAAP variants with enhanced capabilities. Through iterative rounds of packaging MAAP variants into an AAV2 capsid, researchers observed a gradual increase in overall titer and the ratio of secreted vector genomes within the MAAP library population. Notably, specific MAAP variants exhibited augmented abilities to package transgenes in AAV2, AAV6, and AAV9 capsids. These findings not only deepen our understanding of AAV biology but also present a promising avenue for optimizing recombinant AAV manufacturing. This advancement holds significant implications for the biotechnology industry, offering a potential game-changer in the efficiency and scalability of gene therapy manufacturing. As we navigate the frontier of gene therapy, these insights pave the way for more robust and streamlined processes. For those inclined towards a more detailed exploration, the full article by Schieferecke et al. can be accessed here. Special commendations to the authors for their groundbreaking contribution to advancing the landscape of gene therapy manufacturing! #GeneTherapy #BiotechInnovation #AAVManufacturing #DirectedEvolution

Cell and gene therapy (C&GT) manufacturing is complex and far from standardization. In our latest interview, Jean-Simon Diallo, Virica’s CEO and Scientific Founder and Jondavid de Jong, VP of Scientific Operations, break down the key challenges of C&GT manufacturing and the need for tailored solutions to address these issues. Here are the top 3 insights: 💡 There is no “silver bullet” to tackle manufacturing bottlenecks. A winning strategy combines synergistic technologies for additive enhancement. 💡 There is an increasing emphasis on viral vector quality metrics, given the complexity of C&GT manufacturing and the “product is the process”. 💡 Cellular antiviral defenses pose a significant challenge to the yield and quality of viral vectors, making it imperative to address them during viral vector manufacturing. Ultimately, the goal is to make informed process optimizations and sustainably address the manufacturing barriers for cell & gene therapies. Attending Cell & Gene Manufacturing & Commercialization Dubin and want to learn more? Connect with Jean-Simon Diallo and Zeeshan Shaikh, to discover how Viricaᵀᴹ addresses these challenges with Viral Sensitizer (VSEᵀᴹ) technology. 🤝 Partnering platform link: https://lnkd.in/gA_jDDFR 👉 Visit our website to learn more: https://lnkd.in/e3zvChi #innovation #biomanufacturing #CGTEurope